Table 1 Characteristics of the included studies
Study | Country | Phase | EGFR 19del/L858R mutation (no.) | Treatment | Sample size (no.) | PFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|
Stinchcombe 2019 | US | II | 59/29 | Combination therapy Monotherapy | 43 45 | 17.9 13.5 | 32.4 50.6 |
JO25567 2020 | Japan | II | 80/72 | Combination therapy Monotherapy | 75 77 | 16.4 9.8 | 47.0 47.4 |
NEJ026 2021 | Japan | III | 111/113 | Combination therapy Monotherapy | 112 112 | 16.9 13.3 | 50.7 46.2 |
CTONG1509 2021 | China | III | 161/150 | Combination therapy Monotherapy | 157 154 | 17.9 11.2 | 36.2 31.6 |
BEVERLY 2021 | Italy | III | 88/66 | Combination therapy Monotherapy | 80 80 | 15.4 9.6 | 33.3 22.8 |